Low serum 25(OH)D3 in patients newly diagnosed with T2DM

(HealthDay)—Serum 25-hydroxyvitamin D₃ (25[OH]D₃) is associated with glucose-stimulated insulin secretion and β-cell function in individuals with newly diagnosed type 2 diabetes, according to a study published online June 5 in the Journal of Diabetes Investigation.

Yan Yang, from the Sichuan Provincial People's Hospital in Chengdu, China, and colleagues recruited 97 newly diagnosed type 2 diabetes patients and 69 healthy controls to assess 25(OH)D₃. The authors determined 25(OH)D₃ using high pressure liquid chromatography. The correlations of 25(OH)D₃ with insulin resistance and β-cell function were assessed.

The researchers found that patients with newly diagnosed type 2 diabetes had much lower serum 25(OH)D₃ (P < 0.01); the prevalence of hypovitaminosis 25(OH)D₃ in patients with diabetes was 62.9 percent. Among patients with diabetes, those with hypovitaminosis 25(OH)D₃ had higher hemoglobin A1c (HbA1c) and area under the curve for glucose (P < 0.01) and lower homeostasis model of assessment (HOMA)-β, early-phase insulin secretion index, and area under the insulin curve. There was an independent positive correlation for serum 25(OH)D₃ with early-phase insulin secretion index and area under the insulin curve (P < 0.05), but not with HOMA-insulin resistance or HOMA-β. In both groups, triglycerides, HbA1c, and early-phase insulin secretion index were independent factors associated with serum 25(OH)D₃.

"Serum 25(OH)D₃ is not correlated with basal insulin resistance or β-cell function but is significantly positively correlated with glucose-stimulated insulin secretion and β-cell function," the authors write.

Copyright © 2015 HealthDay. All rights reserved.